201 related articles for article (PubMed ID: 25685858)
61. [Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease].
Ozawa T; Kosugi S; Kito M; Onishi M; Kida T; Nakata S; Take H; Katagiri S
Rinsho Ketsueki; 2014 Mar; 55(3):350-5. PubMed ID: 24681940
[TBL] [Abstract][Full Text] [Related]
62. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
63. Current diagnosis and treatment of Castleman's disease.
González García A; Moreno Cobo MÁ; Patier de la Peña JL
Rev Clin Esp (Barc); 2016 Apr; 216(3):146-56. PubMed ID: 26749192
[TBL] [Abstract][Full Text] [Related]
64. [Castleman's disease located in the central nervous system].
Delmont E; Lonjon M; Michiels JF; Chanalet S; Bourg V; Xerri L; Bondiau PY; Lebrun C
Rev Neurol (Paris); 2003 May; 159(5 Pt 1):581-5. PubMed ID: 12773906
[TBL] [Abstract][Full Text] [Related]
65. [Castleman's disease].
Tóth P; Sipos J; Hafner J
Orv Hetil; 2000 Apr; 141(14):729-32. PubMed ID: 10803015
[TBL] [Abstract][Full Text] [Related]
66. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.
Rossi JF; Négrier S; James ND; Kocak I; Hawkins R; Davis H; Prabhakar U; Qin X; Mulders P; Berns B
Br J Cancer; 2010 Oct; 103(8):1154-62. PubMed ID: 20808314
[TBL] [Abstract][Full Text] [Related]
67. [Generalized Castleman's disease associated with Kaposi's sarcoma].
Reverter JC; Nomdedeu B; Martín Ortega E; Llebaría C; Palou J; Rozman C
Rev Clin Esp; 1988 Mar; 182(4):206-9. PubMed ID: 3413312
[No Abstract] [Full Text] [Related]
68. [Expression of interleukin-6 and its clinicopathological significance in Castleman's disease].
Lai YM; Li M; Liu CL; Huang X; Yu GH; Wang XY; Sun L; Chen J; Gao ZF
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):404-8. PubMed ID: 23688750
[TBL] [Abstract][Full Text] [Related]
69. [Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6].
Nakamura H; Nakaseko C; Ishii A; Kogure K; Kawano E; Hashimoto S; Nishimura M; Matsuura Y; Oh H; Yoshida S
Rinsho Ketsueki; 1993 Feb; 34(2):212-7. PubMed ID: 8492420
[TBL] [Abstract][Full Text] [Related]
70. [Clinical significance of cytokines-interleukin 6 in disease].
Yoshizaki K
Rinsho Byori; 1990 Apr; 38(4):375-9. PubMed ID: 2366383
[TBL] [Abstract][Full Text] [Related]
71. Population pharmacokinetics of siltuximab: impact of disease state.
Nikanjam M; Yang J; Capparelli EV
Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
[TBL] [Abstract][Full Text] [Related]
72. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
73. Castleman's Disease and Interleukin 6.
Yabuhara A; Komiyama A
Leuk Lymphoma; 1990; 2(6):369-80. PubMed ID: 27457040
[TBL] [Abstract][Full Text] [Related]
74. [IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions].
Tanaka T
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):433-42. PubMed ID: 27118330
[TBL] [Abstract][Full Text] [Related]
75. Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.
Maeshima A; Nakasatomi M; Henmi D; Yamashita S; Kaneko Y; Kuroiwa T; Hiromura K; Nojima Y
CEN Case Rep; 2012 May; 1(1):7-11. PubMed ID: 28509146
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of Siltuximab and 1,927 nm Fractional Laser for the Treatment of Cutaneous Manifestations in Castleman's Disease: The Role of Dermoscopy and Reflectance Confocal Microscopy for Lesion Evaluation.
Paolino G; Ardigò M; Della-Torre E; Moroni L; Rizzo N; Nicola MRD; Bianchi VG; Dagna L; Ramirez GA; Mercuri SR
Case Rep Dermatol; 2024; 16(1):97-101. PubMed ID: 38590388
[TBL] [Abstract][Full Text] [Related]
77. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
[TBL] [Abstract][Full Text] [Related]
78. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
Patel M; Ikeda S; Pilat SR; Kurzrock R
JAMA Dermatol; 2017 May; 153(5):449-452. PubMed ID: 28241173
[TBL] [Abstract][Full Text] [Related]
79. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
Ohsugi Y; Tsuchimoto N
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
[No Abstract] [Full Text] [Related]
80. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
